PHASE II RANDOMIZED STUDY OF MAINTENANCE TREATMENT WITH BEVACIZUMAB OR BEVACIZUMAB PLUS METRONOMIC CHEMOTHERAPY AFTER FIRST-LINE INDUCTION FOLFOXIRI PLUS BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER PATIENTS

Trial Profile

PHASE II RANDOMIZED STUDY OF MAINTENANCE TREATMENT WITH BEVACIZUMAB OR BEVACIZUMAB PLUS METRONOMIC CHEMOTHERAPY AFTER FIRST-LINE INDUCTION FOLFOXIRI PLUS BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER PATIENTS

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Cyclophosphamide; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms MOMA
  • Most Recent Events

    • 06 Jun 2017 Results (n=482) of pooled analysis of TRIBE and MOMA studies presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 11 Oct 2016 Primary endpoint (Progression-free survival) has been met according to the results presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top